© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of May 20, 2016, the consensus forecast amongst 34 polled investment analysts covering AstraZeneca plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Jan 20, 2016. The previous consensus forecast advised investors to hold their position in AstraZeneca plc.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for AstraZeneca PLC. View Full Financials
In 2015, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 29 analysts covering the company expect dividends of 2.79 USD for the upcoming fiscal year, maintaining dividends from this year. View Full Financials
|Div growth (TTM)||0.00%|
On Apr 29, 2016, AstraZeneca plc reported 1st quarter 2016 earnings of 0.95 per share. This result was in line with the consensus of the 16 analysts following the company and under-performed last year's 1st quarter results by 12.04 %.
The next earnings announcement is expected on Jul 28, 2016. View Full Interim Financials
|Average growth rate||-2.68 %|
AstraZeneca plc reported annual 2015 earnings of 4.26 per share on Feb 04, 2016. View Full Annual Financials
|Average growth rate||-12.22 %|
AstraZeneca PLC had 1st quarter 2016 revenues of 6.12bn. This bettered the 5.95bn consensus of the 15 analysts covering the company. This was 0.96% above the prior year's 1st quarter results. View Full Interim Financials
|Average growth rate||+0.33 %|
AstraZeneca PLC had revenues for the full year 2015 of 23.64bn. This was 9.40 % below the prior year's results. View Full Annual Financials
|Average growth rate||-8.18 %|